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A B S T R A C T
Brain health relies on a tightly regulated system known as neurovascular coupling whereby the cellular con-
stituents of the neuro-glial-vascular unit (NGVU) regulate cerebral haemodynamics in accordance with brain
metabolic demand. Disruption of neurovascular coupling impairs brain health and is associated with the devel-
opment of a number for neurological conditions, including Alzheimer’s disease. The NGVU is also a key site of
action for neuroinflammatory responses and contributes to the transition of systemic inflammation to neuro-
inflammatory processes. Thus, systemic inflammatory challenges may cause a shift in NGVU operation towards
prioritising neuroinflammatory action and thus altering neurovascular coupling and resultant cerebrovascular
changes. To investigate this, rats were injected with lipopolysaccharide (LPS) (2 mg/kg) to induce a systemic
inflammatory response, or vehicle, and brain haemodynamic responses to sensory and non-sensory (hypercapnia)
stimuli were assessed in vivo using optical imaging techniques. Following imaging, animals were perfused and
their brains extracted to histologically characterise components of the NGVU to determine the association be-
tween underlying cellular changes and in vivo blood flow regulation. LPS-treated animals showed changes in
haemodynamic function and cerebrovascular dynamics 6 hours after LPS administration. Histological assessment
identified a significant increase in astrogliosis, microgliosis and endothelial activation in LPS-treated animals. Our
data shows that an acutely induced systemic inflammatory response is able to rapidly alter in vivo haemodynamic
function and is associated with significant changes in the cellular constituents of the NGVU. We suggest that these
effects are initially mediated by endothelial cells, which are directly exposed to the circulating inflammatory
stimulus and have been implicated in regulating functional hyperaemia.
1. Background
Brain health and function are dependent on a comprehensively
regulated blood supply. The local regulation of blood flow and cerebro-
vascular function in accordance with brain metabolic demand is termed
neurovascular coupling and is orchestrated by the resident cells of the
neuro-glial-vascular unit (NGVU). Disruption to neurovascular coupling
can impair the delivery of critical substrates to brain cells and impede the
removal of by-products accumulated during cerebral metabolism (Giro-
uard and Iadecola, 2006). Alterations of brain microenvironment and
cellular interactions of the NGVU have been implicated in the develop-
ment of a number of neurodegenerative diseases, including Alzheimer’s
disease (AD) (De Strooper and Karran, 2016; Sweeney et al., 2015;
Zlokovic, 2011). Nevertheless the process or processes by which neuro-
vascular coupling affects, and is affected by, neurodegenerative diseases
in vivo, as well as the cellular substrates of these effects, remain unclear.
Neurovascular coupling underpins the physiological basis of non-
invasive functional neuroimaging techniques, including functional
magnetic resonance imaging (fMRI) positron emission tomography (PET)
and infra-red spectroscopy (NIRS) in which changes to brain blood flow
and oxygenation are tracked as surrogate markers for neuronal activity.
Such neuroimaging techniques may provide new opportunities to pre-
dict, detect, diagnose and study brain disease processes using non-
invasive imaging biomarkers. However, these possibilities are depen-
dent on our understanding of the mapping of in vivo functional imaging
measurements to neuropathological changes and this may itself be
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affected by specific disease processes such as inflammation.
Mounting evidence highlights inflammation as a major factor in the
development of many neurodegenerative diseases (Cunningham, 2013;
Frank-Cannon et al., 2009; Gao et al., 2011; Heppner et al., 2015).
Further evidence pinpoints inflammation as a driver of neuropathology
(Krstic et al., 2012) and it has been shown to precede the development of
amyloid-beta (Aβ) plaques (Wright et al., 2013). The NGVU is the site of
action of neuroinflammatory responses and contributes to the transition
of systemic inflammation to neuroinflammatory processes. Several
non-neuronal cells within the NGVU are key players in the initiation and
regulation of brain inflammatory responses, as well as in mediating the
effects of systemic inflammation upon brain function. Activated astro-
cytes andmicroglia release a range of pro-inflammatorymolecules (Saijo
et al., 2009; Boche et al., 2013; Sofroniew, 2009; Sofroniew and Vinters,
2010). Endothelial cells (ECs) also play an important role through
upregulation of intercellular adhesion molecules (ICAM-1) and vascular
cellular adhesionmolecules (VCAM-1) (Huber et al., 2006). Researchhas
also highlighted a beneficial role for inflammation, suggesting that
activating the inflammatory responsemay be ofmore therapeutic benefit
than suppressing it (Buckwalter and Wyss-Coray, 2004; Wyss-Coray and
Mucke, 2002). Glial cells have been shown to have a neuroprotective role
in the neuroinflammatory response (Morgan et al., 2004; Polazzi et al.,
2001; Bush et al., 1999; Chen et al., 2001), highlighting the complexity
and difficulty in pinpointing the roles and factors involved in the path-
ophysiological cascade of inflammation.
To help elucidate the changes that occur in the context of inflam-
mation, numerous models have been developed. The peripheral lipo-
polysaccharide (LPS) injection method is a standard technique of
inducing inflammation both in vivo (Hauss-Wegrzyniak et al., 1998;
Pintado et al., 2012) and in vitro (Lehnardt et al., 2003). Depending on
dosage, LPS treated animals display behavioural as well as cellular brain
changes, predominately associated with glial activation (Nazem et al.,
2015; Zakaria et al., 2017). The current study investigated how acute
systemic inflammation impacts upon in vivo cerebrovascular function and
the status of the underlying NGVU cells. This was investigated with a
complementary set of in vivo neuroimaging measures in a rat model,
paired with detailed characterisation of the cellular pathology of the
NGVU in the same animals using immunohistochemistry methods.
2. Methods
The present study was approved by the UK Home Office under the
Animals (Scientific Procedures) Act 1986 and the University of Sheffield
Animal Welfare and Ethical Review Body (AWERB, local ethics
committee). All procedures were conducted under a U.K. Home office
licence and have been reported in accordance with the ARRIVE
guidelines.
2.1. Animals and pharmacological treatment
Female Hooded Lister rats (3–4 months old, 220g–320g) kept at a 12-
h light/dark cycle environment at a temperature of 22 C with access to
food and water ad libitum were housed in polycarbonate cages (n ¼ 3 per
cage) in the Biological Services Unit at the University of Sheffield. Ani-
mals were fed conventional laboratory rat food. Sixteen animals were
randomly assigned to one of two groups (control n ¼ 8 or LPS, n ¼ 8).
Haemodynamic data were acquired in all treatment groups at both 4 and
6 h after LPS/vehicle administration, to characterise any effects of the
acutely induced LPS inflammatory response (Fig. 1).
Each animal received an intraperitoneal injection based on condition.
Control animals were administered a saline vehicle (1 ml/kg), LPS ani-
mals received a dose of 2 mg/kg LPS-EB (lipopolysaccharide from E.coli,
0111:B4 stain-TLR4 ligand, InvivoGen, Europe) dissolved in endotoxin-
free water (InvivoGen, Europe), following loss of consciousness from
anaesthesia.
2.2. Surgical procedures
Details of surgical and experimental paradigms were similar to those
reported in previous publications from this laboratory (Hewson-Stoate
et al., 2005; Jones et al., 2001; Martindale et al., 2003). Briefly, rats were
anaesthetised with an intraperitoneal injection (i.p.) of urethane (1.25
mg/kg in 25% solution), with additional doses of anaesthetic (0.1 ml)
administered if necessary. Choice of anaesthetic was determined by
urethane’s suitability for invasive surgery as well as long-lasting stability,
which is essential in experiments where data collection lasts several
hours (Angel and Gratton, 1982). Anaesthetic depth was initially deter-
mined by means of hindpaw pinch and corneal reflex testing. During data
acquisition continuous blood pressure monitoring did not reveal physi-
ological responses to our whisker stimulation protocol, which would
have been indicative of inadequate anaesthetic depth. Animals were
tracheotomised to allow artificial ventilation and regulation of respira-
tory parameters. A left femoral artery cannulation was performed for
mean arterial blood pressure (MABP) monitoring and blood gas analysis.
A left femoral vein cannulation was also performed to allow continuous
administration of phenylephrine in order to maintain blood pressure
within a healthy physiological range (100–110 mmHg) (Golanov et al.,
1994).
Fig. 1. Experimental timeline. Graphical representation of study design and timeline from non-recovery general anaesthesia to tissue collection. Time (minutes or
hours) is given from time of injection (0 min).
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To enable haemodynamic recordings, the skull was exposed via a
midline incision and a section overlying the left somatosensory cortex
(barrel cortex) was thinned to translucency with a dental drill. This
section was located 1–4 mm posterior and 4–8 mm lateral to Bregma
(Chapin and Lin, 1984). A thinned skull was typically 100–200 μm thick
with the cortical surface vasculature clearly observable. Care was taken
during thinning to ensure that the skull remained cool by frequently
bathing the area with saline.
2.3. Physiological monitoring
Temperature was maintained at 37 C (0.5 C) throughout surgical
and data collection procedures with the use of a homoeothermic blanket
and rectal temperature probe (Harvard Apparatus, USA). Animals were
artificially ventilated with room air using a small animal ventilator (SAR
830, CWE Inc, USA); the breathing rate of each animal was assessed and
modified according to each individual animal’s blood gas measurements.
Respiration rates of the animals ranged from 68 to 74 breaths per minute.
Blood pressure was monitored during the experiment with a pressure
transducer (Wockhardt, UK, 50 units of heparin per mL). Arterial blood
from the femoral artery was allowed to flow back from the cannula into a
cartridge (iSTAT CG4þ, Abbott Point of Care Inc., USA) and blood gases
were analysed to ensure normoxia and normocapnia using a blood gas
analyser (VetScan, iSTAT-1, Abaxis, USA). Physiological parameters
were within normal ranges throughout the experiment (mean values:
PO₂ ¼ 80 mmHg(9.1) PCO₂ ¼ 30.4 mmHg(3.7) SO₂ ¼ 96%(1.2)).
Total volume of arterial blood extracted at one time did not surpass 95
μL. Phenylephrine (Sigma, Aldrich) was administered into the left
femoral vein using a syringe pump (Sp200i, World Precision Instruments
Inc., USA) to counteract reduced blood pressure caused by anaesthesia.
The dose was adjusted according to the blood pressure of each individual
animal but remained in the range of 0.6–2.0 mg/hr.
2.4. Imaging
Cerebral blood flow (CBF) data were acquired with a laser speckle
contrast imaging (LSCI) camera (Full field Laser Perfusion Imager (FLPI-
2), Moor Instruments, UK) which was positioned above the thinned
cranial window. Images were acquired at 25Hz with a spatial resolution
of approximately 10μm/pixel. A 70s baseline data acquisition was ac-
quired to obtain a measure of baseline blood flow. A 3-D dataset
comprising 2-D images of CBF changes over time was written to a com-
puter hard-disk drive by proprietary software (Moor Instruments, UK).
The two-dimensional optical imaging spectroscopy (2D-OIS) tech-
nique was used to estimate activity-induced changes in oxygenated
(HbO2), deoxygenated (HbR) and total (HbT) haemoglobin concentra-
tion in the rat barrel cortex. This technique has been previously described
in detail (Berwick et al., 2005; Sharp et al., 2015). 2D-OIS data were
collected at a frame rate of 8Hz and written to a computer hard-disk drive
using software of in-house design. Subsequent off-line spectral analysis,
conducted using MatLab, was based on the path length scaling algorithm
(PLSA) (Berwick et al., 2005), which uses a modified Beer-Lambert Law
with a path length correction factor. In our analysis, baseline haemo-
globin concentration in the tissue was estimated to be 104 μm based on
previous measurements (Kennerley et al., 2005) and oxygen saturation
estimated to be 50% when breathing room air. Changes in haemoglobin
oxygenation and saturation were thus calculated on a pixel by pixel basis,
before conversion to 3-D datasets (2-D images over time) for HbO2, HbR
and HbT changes.
2.5. Stimulation paradigms
Stimulation of the whisker pad was delivered via two subdermal
stainless steel needle electrodes (12 mm  0.3 mm, Natus neurology
Incorporated, USA) directly inserted into the whisker pad which trans-
mitted an electrical current (1.0 mA). This intensity has been shown to
evoke a robust haemodynamic response without altering physiological
factors such as blood pressure and heart rate. The whiskers were stimu-
lated at one of six frequencies (1, 2, 5, 10, 20 & 40Hz), for 2s with a
stimulus pulse width of 0.3ms. The order of stimulation frequencies was
pseudorandomised with 10 trials at each frequency and an inter-trial
interval (ISI) of 25s. The electrical current is generated by an indepen-
dent amplifier (Isolated Stimulator DS3, Digitimer Ltd., UK) which
directly attaches to the electrodes. All stimulation paradigms were car-
ried out commencing at 4 and 6 h after LPS/vehicle administration.
2.6. Hypercapnia challenge
A hypercapnia challenge was used as a measure of vascular reactivity,
independent of neuronal activity changes. During hypercapnia, a 10%
concentration of carbon dioxide in medical air (9L medical air, 1L CO₂)
was administered to the air supply tube of the ventilator. Thirty-second
long challenges were repeated four times at intervals of 210s in the
absence of whisker stimulation. An interval of 210s ensured that the
animal’s physiological parameters returned to baseline levels before
delivering the next challenge. These challenges were performed
following the whisker stimulation paradigm.
2.7. Perfusion
Rats (n ¼ 11) were transcardially perfused 8 h after LPS/vehicle
administration (following in vivo data collection) with saline (0.9%
warmed to 37 C) with the addition of heparin (0.1ml/500 ml) to exsan-
guinate the vessels, and subsequently fixed in 4% paraformaldehyde (PFA)
01.MpH7.4 in PBS. Saline and fixative were administered through a pump
(Masterflex L/S, Cole-Parmer Instrument Company, UK) at a rate of 34ml/
hr. Brains were stored in PFA overnight at 4 C, sub-dissected into four
regions, and embedded in paraffin wax. Serial sections (5 μm) were cut
from the paraffin-embedded tissue.
2.8. Immunohistochemistry
Immunohistochemistry was performed using a standard avidin-biotin
complex-horse radish peroxidase (ABC-HRP) method, and visualised
with diaminobenzidine ([DAB], Vector Laboratories, UK). A summary of
utilised primary antibodies and their conditions of use are shown in
Table 1. Isotype and no primary antibody controls were included in every
run and no specific immunoreactivity was observed.
2.9. Data processing and analysis
2.9.1. In vivo imaging data
Data were processed in Matlab (2016a) using custom written code.
The same analysis approach was used for the 2D-OIS and LSCI data. Pre-
processed (see Section 2.5) 3-D imaging datasets (2-D spatial images,
over time) were spatially smoothed and then analysed using SPM (The
FIL Methods Group U, 2016), which was implemented through a
graphical user interface constructed in Matlab. SPM produces a thresh-
olded activation map, from which regions of interest (ROIs) were
selected. Each ROI included contributions from arterial, venous and
parenchymal (capillary bed) compartments of the visible cortical surface.
Table 1
Antibody sources and experimental conditions.
Antibody Isotype Dilution (time,
temp)
Antigen retrieval Supplier
Anti-
GFAP
Rabbit
IgG
1:1000 (1 hr RT) MW 10 min, pH9 Dako, UK
Anti-IBA1 Rabbit
IgG
1:400 (1 hr RT) MW 10 min, pH9 Abcam,
UK
ICAM-1 Goat IgG 1:400 (1 hr RT) MW 10 min, TSC pH
6.5
R&D, UK
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Analysis of the 2D-OIS data, which included datasets for concomitant
changes in HbO2, HbR and HbT, was carried out for the HbT changes and
the same ROI was used to extract HbO2 and HbR time series. Two ani-
mals, one from each group, were excluded from final analysis due to the
absence of well-localised stimulus-evoked responses, thereby a total n ¼
14 was used for final analyses (n ¼ 7 for each group). ROI size was
consistent across animals, for both LSCI (F(1,13) ¼ 0.06, p ¼ .811) and
OIS (F(1,13) ¼ 1.54 p ¼ .239) data. LSCI and 2D-OIS time series of
haemodynamic changes for each stimulation trials were then extracted
from the ROI. LSCI time series were down-sampled to 5Hz (from 25Hz).
Data from each stimulation trial were extracted and divided by the
pre-stimulus baseline period (10s), to yield a measure of percentage
change (fractional changes) in CBF, HbO2, HbR and HbT. Time series
were averaged across trials according to stimulation condition. Area
under the curve (AUC) and maxima for each response were calculated.
Statistical comparisons between groups using maxima and AUC
response values were performed using multivariate ANOVAs (MAN-
OVAs) for each time point (4 and 6 h). A p value below .05 was
considered to be a significant effect. Additional independent sample t-
tests were conducted to further probe differences between experimental
conditions. All statistical analyses were conducted using SPSS 23.
2.9.2. Immunohistochemistry data
All images were taken from the contralateral somatosensory cortex
(SS) of the thinned cranial window (right side), to ensure inflammatory
effects were not surgery (thinned cranial window) dependent. As a
further control, images from the hippocampal CA1 region were taken and
quantified. In the SS cortex three adjacent belt transects from the outer
cortex through to the white matter border were taken for each animal at
x20 magnification (Nikon microscope). SS area coordinates for captured
images were taken between 0.40 to 1.80 from Bregma (B) (Paxinos
andWatson, 1998). In the hippocampus, random field images were taken
for each animal in CA1 region, area coordinates for captured images were
between3.30 to5.30 from B (Paxinos andWatson, 1998). Percentage
GFAP, IBA-1 and ICAM-1 area immunoreactivity was quantified using
AnalysisD software. All slides were imaged and analysed blind in a
randomised order. One vehicle animal was excluded from analysis due to
infection. Statistical analyses (independent sample t-tests) were per-
formed using SPSS 23. A p value below .05 was deemed significant.
3. Results
3.1. Acute LPS treatment does not change baseline CBF
To assess any effects of treatment upon baseline CBF, the average
perfusion value across a 30s period prior to the onset of stimulation at the
start (4 h after LPS or saline administration) and at the end of the exper-
imental protocol (6 h after LPS or saline administration) was calculated for
each animal. A mixed design ANOVA on experimental group and time-
point revealed no significant main effect of time (4 vs. 6 h; F(1,13)
¼ 0.98 p¼ .34) or treatment group (LPS vs. saline; F(1,13)¼ 0.32, p¼ .58)
and no significant interaction effect of time and group (F(1,13)¼ 1.02,
p¼ .33). Because laser speckle values are semi-quantitative and may be
affected by minor differences in experimental setup between animals, we
also calculated the relative change in perfusion baselines between the 4 h
and 6 h time-points within each animal. A one-way ANOVA revealed no
significant differences in changes in perfusion baseline over this time
period between the experimental groups (F(1,13) ¼ 0.87, p¼ .37).
3.2. Acute LPS treatment alters cerebrovascular responses to whisker
stimulation
Multivariate analyses of variance (MANOVAs) were applied to HbO2,
HbR, HbT and CBF response maxima or minima (HbR) values in order to
determine significant effects of LPS administration at 4 h and at 6 h post
treatment. All cases (n ¼ 14) were included in the analysis. At 6 h, LPS
administration altered the profile of haemodynamic responses across the
investigated stimulation frequency range with a significant interaction
between stimulation frequency and (LPS or vehicle) treatment (F(20,
190) ¼ 2.31, p ¼ .002; Wilks’ Λ ¼ 0.486). There were also significant
univariate interaction effects for each haemodynamic measure as re-
ported in Table 2. Post hoc analysis of individual stimulation frequencies
using independent t-tests (Fig. 2 A) was used to assess if any particular
frequency was more salient in driving the above interaction effect. Re-
sults indicate a significant increase in HbO2 (p ¼ .0496) and HbR (p ¼
.022) response magnitude at 5Hz following LPS treatment. A represen-
tative haemodynamic response profile at a 5Hz stimulation frequency is
plotted in Fig. 2 B for each measure.
At 4 h post injection, response magnitudes are increased (HBO2, HBT,
CBF) or decreased (HbR) and are especially evident in the 5Hz stimula-
tion trials (Fig. 2), but this is not supported by a MANOVA, with no
significant interaction between stimulation frequency and treatment
(F(20, 190) ¼ 1.34, p ¼ .156; Wilks’ Λ ¼ 0.645).
At both time-points treatment condition by itself did not result in any
significant effect on response magnitudes (4 h: F(4,9) ¼ 0.33, p ¼ .852;
Wilks’ Λ ¼ 0.872; 6 h: F(4,9) ¼ 1.25, p ¼ .357; Wilks’ Λ ¼ 0.643). Thus
Table 2
Summary of univariate statistics for haemodynamic responses to a mixed fre-
quency 2s stimulation paradigm.
Time Factor df F p
4 h after LPS/vehicle
administration
Frequency HbO2 5,60 15.19 <
.001
HbR 5,60 18.68 <
.001
HbT 5,60 11.80 <
.001
CBF 5,60 17.98 <
.001
Frequency x
Treatment
HbO2 5,60 0.76 ¼
.581
HbR 5,60 1.45 ¼
.219
HbT 5,60 0.54 ¼
.743
CBF 5,60 0.23 ¼
.949
Treatment HbO2 1,12 0.10 ¼
.758
HbR 1,12 0.24 ¼
.635
HbT 1,12 0.02 ¼
.892
CBF 1,12 0.15 ¼
.703
6 h after LPS/vehicle
administration
Frequency HbO2 5,60 21.45 <
.001
HbR 5,60 23.86 <
.001
HbT 5,60 15.25 <
.001
CBF 5,60 19.13 <
.001
Frequency x
Treatment
HbO2 5,60 6.48 <
.001
HbR 5,60 7.92 <
.001
HbT 5,60 4.75 ¼
.001
CBF 5,60 2.64 ¼
.032
Treatment HbO2 1,12 1.21 ¼
.294
HbR 1,12 2.36 ¼
.151
HbT 1,12 0.43 ¼
.524
CBF 1,12 0.07 ¼
.798
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Fig. 2. Haemodynamic response to 2s whisker stimulation at six frequencies at 4 h and 6 h after LPS/saline vehicle administration. (A) Bar charts show
percentage (%) change at maxima or minima (HbR). Post hoc analysis on stimulation frequencies reveal significant effects at 5Hz for HbO2 and HbR (*denotes
significant differences at p < .05) between groups (B) Representative 5Hz time series showing mean fractional changes. Grey rectangle indicates stimulation onset/
offset and error bars indicate standard error of the mean.
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although a consistent trend in increases in haemodynamic response was
observed in LPS-treated animals, the interaction with stimulation fre-
quency was key in driving significant differences between groups.
At both time points there was a significant effect of stimulation fre-
quency on haemodynamic response magnitude (4 h: F(20, 190) ¼ 7.042,
p < .001; Wilks’ Λ ¼ 0.159; 6 h: F(20, 190) ¼ 6.41, p < .001; Wilks’ Λ ¼
0.181 [Fig. 2 A]), indicating the range of stimulus inputs was effective in
driving responses over a dynamic range, with significant effects for each
haemodynamic response measure (Table 2).
3.3. LPS administration does not change haemodynamic responses to
hypercapnia
Analysis of variance (MANOVA) were used to determine significant
effects of treatment on haemodynamic response magnitude (for HbO2,
HbR, HbT and CBF variables) to a 30s hypercapnia challenge at 4 h and 6
h post treatment. Maxima (or minima for HbR) values were used to
quantify the response. Treatment had no significant effect on response
magnitude at 4 h (F(4,9) ¼ 1.42, p ¼ .304; Wilks’ Λ ¼ 0.613) or at 6 h
(F(4,9) ¼ 1.33, p ¼ .331; Wilks’ Λ ¼ 0.629) (Fig. 3).
3.4. LPS treated animals show a change in the cerebral metabolic rate of
oxygen consumption (CMRO2) following treatment
The method utilised to estimate CMRO2 was as described in (Jones
et al., 2001; Mayhew et al., 2001). Briefly the CMRO2 estimate was
calculated from HbR, HbT and CBF values generated from 2D-OIS and
LSCI data. CMRO2 in the brain is directly linked to cellular energy con-
sumption and neuronal activity (Liu et al., 2014), thus it can provide a
measure to assess the neurovascular coupling relationship by assessing
changes in oxygen delivery or oxygen metabolism. CMRO2 changes in
response to simulation were estimated at both time points (4 h and 6 h)
and for both vehicle and LPS treated animals (Fig. 4). Response maxima
and AUC were calculated and analysed with one-way ANOVA. There was
no significant difference in the responsemaxima between groups at 4 h or
6 h after LPS/vehicle treatment (4 h: F(1,13)¼ 3.5, p¼ .087; 6 h: F(1,13)
¼ 2.5, p ¼ .138). However, for AUC, a one-way ANOVA reveals a sig-
nificant difference between treatment groups at 6 h (F(1,13) ¼ 6.16, p ¼
.029). Inspection of the time-series of changes in Fig. 4 indicate that this
difference is attributable to a substantial below baseline decrease in
CMRO2, following an initial increase, in LPS treated animals. No signif-
icant difference in AUC was found at 4 h (F(1,13) ¼ 2.05, p ¼ .178).
3.5. Acute LPS treatment induces astrogliosis and microgliosis
GFAP immunolabelled the cell body and immediate processes of as-
trocytes in both cohorts (Fig. 5 A). Hypertrophic astrocytes were
observed in LPS cases, indicative of a mild to moderate astrogliosis
phenotype. Levels of GFAP expression, assessed as percentage area
immunoreactivity, showed a significant 74% increase in LPS cases in the
SS cortex (t(8)¼4.15, p¼ .003) (Fig. 5 B). Within the CA1 region of the
hippocampus immunoreactivity was similar to control cases, no signifi-
cant difference was found between LPS and vehicle treated groups (Fig. 5
C), t(8) ¼ 1.94, p ¼ .089 [38% increase]).
IBA1 immunolabelled the cell body and ramified processes of microglia
in both treatment groups (Fig. 5 D). LPS-treated animals displayed a hy-
pertrophic profile, indicative of a reactive microglial phenotype with a
larger, more rounded cell body. Levels of IBA1 expression, assessed as
percentage area immunoreactivity, showed a significant 109% increase in
LPS treated animals in SS cortex (t(8) ¼ 3.84, p ¼ .005) (Fig. 5 E) with
more intense immunolabelling of both the cell body and extending pro-
cesses. In the CA1 hippocampal region, IBA1⁺ microglia immunoreactivity
for LPS treated was also significantly increased (t(8) ¼ 4.09 [119% in-
crease], p ¼ .003, Fig. 5 F).
3.6. Acute LPS treatment increased expression of ICAM-1 on the
endothelial luminal surface and microglia processes
ICAM-1 immunolabelled vessels in both cohort groups although LPS
treated animals showed more intense immunoreactivity compared to
controls (Fig. 6 A). Furthermore, immunolabelling of microglia was a
feature of all LPS cases but was less intense than vessel labelling. Per-
centage area assessment revealed a significant increase in ICAM-1
expression in LPS cases with a 299% area increase in the SS cortex
(t(8) ¼ 6.5, p < .001, Fig. 6 B) and 108% area increase in CA1 (t(8) ¼
4.73, p ¼ .001, Fig. 6 C).
4. Discussion
In this study we present evidence of acute alteration of cerebrovas-
cular function by systemic inflammation, using an animal model treated
with LPS. This was demonstrated by changes in cortical haemodynamic
responses to stimulation, an absence of effects on baseline blood flow or
vascular reactivity, and concomitant cellular changes in the NGVU.
Although direct comparisons of responses to various inflammatory
stimuli between species are difficult, these findings may have implica-
tions for the interpretation of functional neuroimaging data acquired in
clinical and healthy human cohorts; the presence of systemic inflam-
mation may change the haemodynamic response processes which un-
derlie neuroimaging signals (e.g. CBF, cerebral blood volume (CBV) and
CMRO2). In addition, characterisation of NGVU cellular changes via
immunohistochemistry showed morphological changes in astrocytes and
microglia, alongside a marked increase in ICAM-1 expression, indicating
EC activation.
LPS administration significantly changed cerebrovascular function as
indicated by an interaction of stimulation frequency (input to the cortex)
and treatment condition. These effects became evident at 6 h after LPS
administration, although similar (non-significant) trends were observed
at the 4 h time point. The significant effects on cerebrovascular function
were mainly manifested as an increased response at a specific stimulation
frequency (5Hz), although similar trends were indicated at other fre-
quencies. Stimulation frequency dependent effects have been previously
reported in the literature (Spain et al., 2015; Martin et al., 2006) and for
thewhisker system, stimulation frequencies at around5Hz are regarded as
most effective and of functional relevance in driving somatosensory
neurovascular responses in anaesthetised animals (Martin et al., 2006;
Adibi, 2019) andmay therefore represent the point of maximal sensitivity
to treatment effects in this study. These results underline the complexity of
the neurovascular coupling relationships, and the importance of including
a dynamic rangeof sensory stimulation in neurovascular research to better
assess how the neurovascular system responds to different levels of input
in health and under disease-related manipulations.
Hypercapnia is a widely used protocol, in both animal (Martin et al.,
2006) and human (Suri et al., 2015) research studies, for assessing and
comparing cerebrovascular reactivity. Here, we report that the cerebro-
vascular responses to hypercapnia are not significantly changed by LPS
administration. This, together with a lack of evidence of altered baseline
CBF, indicates that the changes in haemodynamic responses to stimula-
tion are thus not a consequence of a generic effect on vascular reactivity
or baseline blood flow, but instead may relate to the function of the
NGVU in translating changes in neural activity into vascular responses,
i.e., neurovascular coupling.
CMRO2 in the brain is considered to be an index of brain health and
energy homeostasis (Liu et al., 2014) as well as being directly linked to
cell energy and neuronal activity (Ge et al., 2012). Estimation of CMRO2
can thus provide a measure to assess the neurovascular dynamics by
assessing possible changes in oxygen delivery or oxidative metabolism.
Our CMRO2 estimates suggest a change in how oxygen delivery is
matched to metabolic demand; where the magnitude of changes in CBF
relative to oxygen consumption is increased by LPS treatment. This may
in turn reflect a change in neurovascular coupling but this requires
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Fig. 3. HbO2 HbR, HbT and CBF response to hypercapnia at 4 h and 6 h after LPS/saline vehicle administration. (A) Time series show mean fractional changes
and (B) bar charts show percentage change at maxima or minima. Grey rectangle indicates the 30s CO2 challenge onset/offset. Error bars represent standard error of
the mean.
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validation with a direct measure of neuronal activity. Our CMRO2 esti-
mates indicate a change in the relationship between the HbR, HbT and
CBF components of the haemodynamic response under LPS treatment,
from which the CMRO2 estimate is made. This would in turn predict that
BOLD fMRI signals, which are also derived from HbR, HbT and CBF
changes, will be different under LPS treatment. Therefore, caution should
be used in interpreting neuroimaging signals acquired from subjects with
systemic inflammation present.
GFAP⁺ astrocytes in LPS-treated animals displayed significantly
greater immunoreactivity of processes and cell bodies, a phenotype
Fig. 4. CMRO2 estimation atþ4 andþ6 after LPS/saline vehicle administration. (A) Time series of estimated CMRO2 changes following whisker stimulation, (B)
Bar chart showing percentage change at maxima and (C) Bar chart showing change in area under the curve (AUC, units are summed percentage change).
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suggestive of mild to moderate astrogliosis (Sofroniew and Vinters,
2010). A non-significant difference between GFAPþ immunoreactivity in
the CA1 region of LPS treated and control animals may be explained by
the dense population of GFAPþ astrocytes in the hippocampus compared
to cortical areas (Gomi et al., 1995; Shibuki et al., 1996), leading to a
high level of baseline immunoreactivity and reduced sensitivity to group
differences. Further quantification utilising other GFAP isoforms along-
side additional astrocyte markers (such as ALDH1L1, nestin, vimentin)
may help to fully elucidate the astrocyte response triggered by an acute
LPS challenge. Similarly, increases in IBA1 expression and a shift from a
ramified ‘resting’morphology to a hypertrophic profile (characterised by
an amoeboid appearance) indicates microgliosis in our LPS treated ani-
mals (Boche et al., 2013; Sun et al., 2008).
ICAM-1 has an important role in cell-to-cell adhesion interactions and
has low expression in cerebral microvessels in normal physiological
conditions (Wertheimer et al., 1992), but is upregulated on the luminal
surface of ECs in the presence of pro-inflammatory mediators (Huber
et al., 2006; da Fonseca et al., 2014). In LPS treated animals, we
demonstrate increased ICAM-1 expression on the luminal surface of ECs,
as well as microglial processes. ECs have already been shown to change
their phenotypes in support of various phases of the inflammatory pro-
cess (Pober and Sessa, 2007; Pober and Cotran, 1990). Furthermore, EC
location at the interface between brain and blood, as well as their
expression of TLR-4 receptors (Verma et al., 2006) (specifically activated
by the LPS strain we used), might indicate these cells as initiators of the
inflammatory response in this study. Alterations in EC function could
then propagate to other NGVU cells, activating astrocytes and microglia.
In support of this, a paper developing a concurrent cell-type specific
isolation method (Swartzlander et al., 2018), reported gene expression
changes (upregulation of pro-inflammatory cytokines, chemokines, cell
adhesionmolecules, including ICAM1) in vascular endothelia in response
to a peripheral LPS challenge. These results indicate that vascular ECs
Fig. 5. LPS-treatment changes in glial
pathology. (A) GFAP immunolabelling of
astrocyte cell body and immediate processes.
(B) GFAP SS percentage area immunoreac-
tivity was significantly increased in LPS
treated animals (74% increase, p ¼ .003) but
was not significantly different in CA1 (p ¼
.089) (C). (D) IBA1 immunolabelling of
microglia cell body and ramified processes.
IBA1 SS (E) and CA1 (F) percentage area
immunoreactivity were significantly
increased in LPS treated animals (SS: 109%
increase, p ¼ .005; CA1: 119% increase p ¼
.003). Scale bar represents 50 μm ** denotes
p < .010 * denotes p < .05.
Fig. 6. LPS-treatment changes in ICAM-1 expression. (A) ICAM-1 immunolabelled vessels and microglia processes. LPS-treatment led to increased percentage area
ICAM-1 immunoreactivity in the SS cortex (B) (299% increase, p < .001) and in the CA1 (C) (108% increase, p ¼ .001). Scale bar represents 50 μm ** denotes p
< .002.
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may be central in the initiation and transmission of the LPS response from
the periphery to the CNS via cytokines, chemokines and extracellular
remodelling (Pober and Cotran, 1990).
ECs have also been implicated as key players in mediating neuro-
vascular coupling in health (Chen et al., 2014). Retrograde dilation of
pial vessels following sensory stimulation is blocked if EC signalling is
interrupted and disruption of ECs at the pial surface leads to a significant
attenuation of the haemodynamic response (Chen et al., 2014). This
could explain the increases in haemodynamic response observed in this
study, where such changes could be mediated by increased activity of ECs
at the pial surface.
CNS resident cells including microglia (Marzolo et al., 2000) and
astrocytes (Chakravarty and Herkenham, 2005) possess TLR-4 receptors
and thus could be directly activated by an LPS challenge, a possibility
that must be considered in the interpretation of our data. However, li-
popolysaccharides and pro-inflammatory molecules are large and thus
should have limited BBB permeability (Holmes, 2013). Evidence from
studies using radioactively labelled LPS (Banks et al., 2015; Banks and
Robinson, 2010) has shown little LPS penetration of the BBB (0.025% of
the administered dose) and only at doses of 3 mg/kg or higher. As such,
in our model, and owing to the acute nature of the study, we do not
anticipate BBB breakdown and extravasation of LPS into the parenchyma
to be amajor factor. This suggests that the observable brain inflammatory
response produced by a peripheral administration of LPS is most likely
mediated and initiated by ECs. It may also be mediated by alternative
routes of communication between the brain and the periphery as opposed
to a direct effect on glial TLR-4 brain receptors (for a comprehensive
review see Holmes, 2013). This could explain why studies comparing
brain and peripheral inflammatory challenges such as the one by Mon-
tacute et al. (2017) report similar levels of brain inflammation in both
challenges.
There is a pressing need to understand the communication pathways
between the peripheral and central immune systems in order to under-
stand the role of inflammation in neurological diseases and ageing.
Neurodegenerative diseases such as AD are characterised by a chronic
low-grade inflammatory response and therefore, a limitation of this study
is the use of an acute experimental design. However, because chronic and
acute inflammatory processes overlap substantially and share some of the
same mediators, including EC activation (Pober and Sessa, 2007), the
effects observed here may still be informative when considering the
chronic case. Relatedly, ageing is also a key factor in both disease pa-
thology and in inflammation but is not investigated in the present study.
As such, future work should aim to extend this model to include low-dose
chronic inflammation and the use of aged animals to maximise the
relevance of findings to human pathology and human ageing.
Whilst we find no evidence of leukocyte extravasation in LPS treated
cases, astrocytes and microglia are highly likely to be contributing to the
neuroinflammatory response by secreting an array of cytokines. Future
work should thus also aim to characterise the inflammatory profile of
glial cells in response to acute systemic inflammation. Lastly, different
species of LPS elicit different cytokines profiles, thereby producing
different classes of immune response in vivo (Pulendran et al., 2001). This
is an important consideration for studies utilising LPS to create an
experimental model of inflammation. The LPS strain utilised in this
study, due to its ultrapure nature, only activates the TLR-4 pathway and
thus offers a robust way of investigating the inflammatory-driven neu-
rovascular and NGVU effects which are mediated by a specific pathway.
5. Implications and conclusion
This study has implications for the understanding of how cerebro-
vascular function changes during in response to acute systemic inflam-
mation. The results support our overall hypothesis that a systemic
inflammatory challenge may impact upon cerebrovascular function
through a shift in the operation of NGVU cells, from neurovascular
regulation to neuroinflammatory response. Changes in cerebrovascular
function and the coupling of local blood flow to fluctuations in neuronal
activity may be of particular importance for human fMRI research studies
which rely on assumptions regarding the short-latency impulse response
function (as measured here by our stimulation protocol) to make in-
ferences about neuronal activity changes from neuroimaging signals
(Logothetis, 2008). Although inflammatory stimuli doses and subsequent
response are not straightforwardly comparable between species, the
findings from the current study may have implications for the application
of fMRI in subjects or patients where a systemic inflammatory response
may be present.
In conclusion, our data shows that an acutely induced systemic in-
flammatory response is able to rapidly change in vivo cerebrovascular
function, with an associated marked immunoreactivity within the
cellular constituents of the NGVU. We hypothesise that the inflammatory
response may be triggered initially by ECs, as these cells are directly
exposed to the bloodstream and have been implicated in mediating
neurovascular coupling in health.
Declarations of competing interest
None.
Acknowledgements
The authors would like to thank the Sheffield Institute for Trans-
lational Neuroscience (SITraN) histopathology technical team, in
particular Lynne Baxter, for their work in preparation of immunohisto-
logical protocols and for providing technical assistance.
List of abbreviations
2D-OIS Two-dimensional optical imaging spectroscopy
Aβ Amyloid-beta
AD Alzheimer’s disease
AQP4 Aquaporin 4
BBB Blood brain barrier
BOLD Blood oxygen level dependence
CBF Cerebral blood flow
CBV Cerebral blood volume
CMRO2 Cerebral metabolic rate of oxygen consumption
DAB 3,30-Diaminobenzidine;
fMRI functional magnetic resonance imaging
GFAP Glial fibrillary acidic protein
HbO2 Oxyhaemoglobin
HbR Deoxyhaemoglobin
HbT Total haemoglobin
IBA1 Ionized calcium binding adaptor molecule 1
ICAM-1 Intercellular adhesion molecule
IL-1 Interleukin 1
LPS Lipopolysaccharide
LSCI Laser speckle contrast imaging
NIRS Near infra-red spectroscopy
NGVU Neuro-glial-vascular unit
VCAM-1 vascular cellular adhesion molecule
PET Positron emission tomography
SS Somatosensory cortex
TLR-4 Toll-like receptor 4
TNF-α Tumour necrosis factor alpha
Funding
This study was supported by The Royal Society [CM, UF130327]; the
Wellcome Trust [CM,WT093223AIA]; theMedical Research Council [CM
& JB, MR/M013553/1]; Alzheimer’s Research UK [JB, KA-A, IRG2014-
10] and The University of Sheffield [GB, PhD Teaching Fellowship].
G. Brezzo et al. Brain, Behavior, & Immunity - Health 5 (2020) 100074
10
Data statement
The datasets used and/or analysed during the current study are
available from the corresponding author on reasonable request.
References
Adibi, M., 2019. Whisker-mediated touch system in rodents: from neuron to behavior.
Front. Syst. Neurosci. 13, 40.
Angel, A., Gratton, D., 1982. A the effect of anaesthetic agents on cerebral cortical
responses in the rat. Br. J. Pharmacol. 76 (4), 541–549.
Banks, W.A., Robinson, S.M., 2010. Minimal penetration of lipopolysaccharide across the
murine blood–brain barrier. Brain Behav. Immun. 24 (1), 102–109.
Banks, W.A., Gray, A.M., Erickson, M.A., Salameh, T.S., Damodarasamy, M., Sheibani, N.,
et al., 2015. Lipopolysaccharide-induced blood-brain barrier disruption: roles of
cyclooxygenase, oxidative stress, neuroinflammation, and elements of the
neurovascular unit. J. Neuroinflammation 12 (1), 223.
Berwick, J., Johnston, D., Jones, M., Martindale, J., Redgrave, P., McLoughlin, N., et al.,
2005. Neurovascular coupling investigated with two-dimensional optical imaging
spectroscopy in rat whisker barrel cortex. Eur. J. Neurosci. 22 (7), 1655–1666.
Boche, D., Perry, V., Nicoll, J., 2013. Review: activation patterns of microglia and their
identification in the human brain. Neuropathol. Appl. Neurobiol. 39 (1), 3–18.
Buckwalter, M.S., Wyss-Coray, T., 2004. Modelling neuroinflammatory phenotypes in
vivo. J. Neuroinflammation 1 (1), 10.
Bush, T.G., Puvanachandra, N., Horner, C.H., Polito, A., Ostenfeld, T., Svendsen, C.N.,
et al., 1999. Leukocyte infiltration, neuronal degeneration, and neurite outgrowth
after ablation of scar-forming, reactive astrocytes in adult transgenic mice. Neuron 23
(2), 297–308.
Chakravarty, S., Herkenham, M., 2005. Toll-like receptor 4 on nonhematopoietic cells
sustains CNS inflammation during endotoxemia, independent of systemic cytokines.
J. Neurosci. 25 (7), 1788–1796.
Chapin, J.K., Lin, C.-S., 1984. Mapping the body representation in the SI cortex of
anesthetized and awake rats. J. Comp. Neurol. 229 (2), 199–213.
Chen, Y., Vartiainen, N.E., Ying, W., Chan, P.H., Koistinaho, J., Swanson, R.A., 2001.
Astrocytes protect neurons from nitric oxide toxicity by a glutathione-dependent
mechanism. J. Neurochem. 77 (6), 1601–1610.
Chen, B.R., Kozberg, M.G., Bouchard, M.B., Shaik, M.A., Hillman, E.M., 2014. A critical
role for the vascular endothelium in functional neurovascular coupling in the brain.
J. Am. Heart Assoc. 3 (3), e000787.
Cunningham, C., 2013. Microglia and neurodegeneration: the role of systemic
inflammation. Glia 61 (1), 71–90.
da Fonseca, A.C.C., Matias, D., Garcia, C., Amaral, R., Geraldo, L.H., Freitas, C., et al.,
2014. The impact of microglial activation on blood-brain barrier in brain diseases.
Front. Cell. Neurosci. 8.
De Strooper, B., Karran, E., 2016. The cellular phase of Alzheimer’s disease. Cell 164 (4),
603–615.
Frank-Cannon, T.C., Alto, L.T., McAlpine, F.E., Tansey, M.G., 2009. Does
neuroinflammation fan the flame in neurodegenerative diseases? Mol. Neurodegener.
4 (1), 1.
Gao, H.-M., Zhang, F., Zhou, H., Kam, W., Wilson, B., Hong, J.-S., 2011.
Neuroinflammation and [alpha]-Synuclein dysfunction potentiate each other, driving
chronic progression of neurodegeneration in a mouse model of Parkinson’s disease.
Environ. Health Perspect. 119 (6), 807.
Ge, Y., Zhang, Z., Lu, H., Tang, L., Jaggi, H., Herbert, J., et al., 2012. Characterizing brain
oxygen metabolism in patients with multiple sclerosis with T2-relaxation-under-spin-
tagging MRI. J. Cerebr. Blood Flow Metabol. 32 (3), 403–412.
Girouard, H., Iadecola, C., 2006. Neurovascular coupling in the normal brain and in
hypertension, stroke, and Alzheimer disease. J. Appl. Physiol. 100 (1), 328–335.
Bethesda, Md : 1985.
Golanov, E., Yamamoto, S., Reis, D., 1994. Spontaneous waves of cerebral blood flow
associated with a pattern of electrocortical activity. Am. J. Physiol. Regul. Integr.
Comp. Physiol. 266 (1), R204–R214.
Gomi, H., Yokoyama, T., Fujimoto, K., Ikeda, T., Katoh, A., Itoh, T., et al., 1995. Mice
devoid of the glial fibrillary acidic protein develop normally and are susceptible to
scrapie prions. Neuron 14 (1), 29–41.
Hauss-Wegrzyniak, B., Dobrzanski, P., Stoehr, J.D., Wenk, G.L., 1998. Chronic
neuroinflammation in rats reproduces components of the neurobiology of
Alzheimer’s disease. Brain Res. 780 (2), 294–303.
Heppner, F.L., Ransohoff, R.M., Becher, B., 2015. Immune attack: the role of
inflammation in Alzheimer disease. Nat. Rev. Neurosci. 16 (6), 358–372.
Hewson-Stoate, N., Jones, M., Martindale, J., Berwick, J., Mayhew, J., 2005. Further
nonlinearities in neurovascular coupling in rodent barrel cortex. Neuroimage 24 (2),
565–574.
Holmes, C., 2013. Review: systemic inflammation and Alzheimer’s disease. Neuropathol.
Appl. Neurobiol. 39 (1), 51–68.
Huber, J.D., Campos, C.R., Mark, K.S., Davis, T.P., 2006. Alterations in blood-brain
barrier ICAM-1 expression and brain microglial activation after λ-carrageenan-
induced inflammatory pain. Am. J. Physiol. Heart Circ. Physiol. 290 (2), H732–H740.
Jones, M., Berwick, J., Johnston, D., Mayhew, J., 2001. Concurrent optical imaging
spectroscopy and laser-Doppler flowmetry: the relationship between blood flow,
oxygenation, and volume in rodent barrel cortex. Neuroimage 13 (6 Pt 1),
1002–1015.
Kennerley, A.J., Berwick, J., Martindale, J., Johnston, D., Papadakis, N., Mayhew, J.E.,
2005. Concurrent fMRI and optical measures for the investigation of the
hemodynamic response function. Magn. Reson. Med. 54 (2), 354–365.
Krstic, D., Madhusudan, A., Doehner, J., Vogel, P., Notter, T., Imhof, C., et al., 2012.
Systemic immune challenges trigger and drive Alzheimer-like neuropathology in
mice. J. Neuroinflammation 9 (1), 1.
Lehnardt, S., Massillon, L., Follett, P., Jensen, F.E., Ratan, R., Rosenberg, P.A., et al., 2003.
Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-
like receptor 4-dependent pathway. Proc. Natl. Acad. Sci. Unit. States Am. 100 (14),
8514–8519.
Liu, P., Huang, H., Rollins, N., Chalak, L.F., Jeon, T., Halovanic, C., et al., 2014.
Quantitative assessment of global cerebral metabolic rate of oxygen (CMRO2) in
neonates using MRI. NMR Biomed. 27 (3), 332–340.
Logothetis, N.K., 2008. What we can do and what we cannot do with fMRI. Nature 453
(7197), 869–878.
Martin, C., Martindale, J., Berwick, J., Mayhew, J., 2006. Investigating
neural–hemodynamic coupling and the hemodynamic response function in the awake
rat. Neuroimage 32 (1), 33–48.
Martindale, J., Mayhew, J., Berwick, J., Jones, M., Martin, C., Johnston, D., et al., 2003.
The hemodynamic impulse response to a single neural event. J. Cerebr. Blood Flow
Metabol. 23 (5), 546–555.
Marzolo, M.P., Von Bernhardi, R., Bu, G., Inestrosa, N.C., 2000. Expression of α2-
macroglobulin receptor/low density lipoprotein receptor-related protein (LRP) in rat
microglial cells. J. Neurosci. Res. 60 (3), 401–411.
Mayhew, J., Johnston, D., Martindale, J., Jones, M., Berwick, J., Zheng, Y., 2001.
Increased oxygen consumption following activation of brain: theoretical footnotes
using spectroscopic data from barrel cortex. Neuroimage 13 (6), 975–987.
Montacute, R., Foley, K., Forman, R., Else, K.J., Cruickshank, S.M., Allan, S.M., 2017.
Enhanced susceptibility of triple transgenic Alzheimer’s disease (3xTg-AD) mice to
acute infection. J. Neuroinflammation 14 (1), 50.
Morgan, S.C., Taylor, D.L., Pocock, J.M., 2004. Microglia release activators of neuronal
proliferation mediated by activation of mitogen-activated protein kinase,
phosphatidylinositol-3-kinase/Akt and delta-Notch signalling cascades.
J. Neurochem. 90 (1), 89–101.
Nazem, A., Sankowski, R., Bacher, M., Al-Abed, Y., 2015. Rodent models of
neuroinflammation for Alzheimer’s disease. J. Neuroinflammation 12 (1), 1.
Paxinos, G., Watson, C., 1998. The Rat Brain in Stereotaxic Coordinates. Academic Press.
Pintado, C., Gavilan, M.P., Gavilan, E., García-Cuervo, L., Gutierrez, A., Vitorica, J., et al.,
2012. Lipopolysaccharide-induced neuroinflammation leads to the accumulation of
ubiquitinated proteins and increases susceptibility to neurodegeneration induced by
proteasome inhibition in rat hippocampus. J. Neuroinflammation 9 (1), 1.
Pober, J.S., Cotran, R.S., 1990. The role of endothelial cells in inflammation.
Transplantation 50 (4), 537–544.
Pober, J.S., Sessa, W.C., 2007. Evolving functions of endothelial cells in inflammation.
Nat. Rev. Immunol. 7 (10), 803–815.
Polazzi, E., Gianni, T., Contestabile, A., 2001. Microglial cells protect cerebellar granule
neurons from apoptosis: evidence for reciprocal signaling. Glia 36 (3), 271–280.
Pulendran, B., Kumar, P., Cutler, C.W., Mohamadzadeh, M., Van Dyke, T., Banchereau, J.,
2001. Lipopolysaccharides from distinct pathogens induce different classes of
immune responses in vivo. J. Immunol. 167 (9), 5067–5076.
Saijo, K., Winner, B., Carson, C.T., Collier, J.G., Boyer, L., Rosenfeld, M.G., et al., 2009.
A Nurr1/CoREST pathway in microglia and astrocytes protects dopaminergic neurons
from inflammation-induced death. Cell 137 (1), 47–59.
Sharp, P.S., Shaw, K., Boorman, L., Harris, S., Kennerley, A.J., Azzouz, M., et al., 2015.
Comparison of stimulus-evoked cerebral hemodynamics in the awake mouse and
under a novel anesthetic regime. Sci. Rep. 5, 12621.
Shibuki, K., Gomi, H., Chen, L., Bao, S., Kim, J.J., Wakatsuki, H., et al., 1996. Deficient
cerebellar long-term depression, impaired eyeblink conditioning, and normal motor
coordination in GFAP mutant mice. Neuron 16 (3), 587–599.
Sofroniew, M.V., 2009. Molecular dissection of reactive astrogliosis and glial scar
formation. Trends Neurosci. 32 (12), 638–647.
Sofroniew, M.V., Vinters, H.V., 2010. Astrocytes: biology and pathology. Acta
Neuropathol. 119 (1), 7–35.
Spain, A., Howarth, C., Khrapitchev, A.A., Sharp, T., Sibson, N.R., Martin, C., 2015.
Neurovascular and neuroimaging effects of the hallucinogenic serotonin receptor
agonist psilocin in the rat brain. Neuropharmacology 99, 210–220.
Sun, J., Zheng, J.H., Zhao, M., Lee, S., Goldstein, H., 2008. Increased in vivo activation of
microglia and astrocytes in the brains of mice transgenic for an infectious R5 human
immunodeficiency virus type 1 provirus and for CD4-specific expression of human
cyclin T1 in response to stimulation by lipopolysaccharides. J. Virol. 82 (11),
5562–5572.
Suri, S., Mackay, C.E., Kelly, M.E., Germuska, M., Tunbridge, E.M., Frisoni, G.B., et al.,
2015. Reduced cerebrovascular reactivity in young adults carrying the APOE ε4
allele. Alzheimer’s Dementia 11 (6), 648–657. e1.
Swartzlander, D.B., Propson, N.E., Roy, E.R., Saito, T., Saido, T., Wang, B., et al., 2018.
Concurrent cell type–specific isolation and profiling of mouse brains in inflammation
and Alzheimer’s disease. JCI insight 3 (13).
Sweeney, M.D., Sagare, A.P., Zlokovic, B.V., 2015. Cerebrospinal fluid biomarkers of
neurovascular dysfunction in mild dementia and Alzheimer’s disease. J. Cerebr.
Blood Flow Metabol. 35 (7), 1055–1068.
The FIL Methods Group U. Statistical parametric mapping (SPM) 2016 [updated 23/06/
2016. Available from. http://www.fil.ion.ucl.ac.uk/spm/.
Verma, S., Nakaoke, R., Dohgu, S., Banks, W.A., 2006. Release of cytokines by brain
endothelial cells: a polarized response to lipopolysaccharide. Brain Behav. Immun. 20
(5), 449–455.
G. Brezzo et al. Brain, Behavior, & Immunity - Health 5 (2020) 100074
11
Wertheimer, S.J., Myers, C.L., Wallace, R.W., Parks, T.P., 1992. Intercellular adhesion
molecule-1 gene expression in human endothelial cells. Differential regulation by
tumor necrosis factor-alpha and phorbol myristate acetate. J. Biol. Chem. 267 (17),
12030–12035.
Wright, A.L., Zinn, R., Hohensinn, B., Konen, L.M., Beynon, S.B., Tan, R.P., et al., 2013.
Neuroinflammation and neuronal loss precede Aβ plaque deposition in the hAPP-J20
mouse model of Alzheimer’s disease. PloS One 8 (4), e59586.
Wyss-Coray, T., Mucke, L., 2002. Inflammation in neurodegenerative disease—a double-
edged sword. Neuron 35 (3), 419–432.
Zakaria, R., Yaacob, W.W., Othman, Z., Long, I., Ahmad, A., Al-Rahbi, B., et al., 2017.
Lipopolysaccharide-induced memory impairment in rats: a model of Alzheimer’s
disease. Physiol. Res. 66 (4), 553–565.
Zlokovic, B.V., 2011. Neurovascular pathways to neurodegeneration in Alzheimer’s
disease and other disorders. Nat. Rev. Neurosci. 12 (12), 723–738.
G. Brezzo et al. Brain, Behavior, & Immunity - Health 5 (2020) 100074
12
